Charlotte Casebourne Stock moves on from Theolytics to next entrepreneurial endeavour

Mike Grey commented: "On behalf of the board and Theolytics' investors we would like to extend our heartfelt appreciation to Charlotte. Without her, Theolytics wouldn't be in the strong position the company finds itself in today. Under Charlotte's leadership, over $40m of dilutive and non-dilutive capital was raised, and in only seven years the company has advanced into the clinic. We respect her decision to pursue new entrepreneurial endeavors, and wish her the very best. I look forward to working with her as an advisor, alongside Theolytics' Board and team to execute on the promising strategy defined."

OXFORD, England, 12/07/2024 (informazione.it - comunicati stampa - salute e benessere)

About Theolytics

Theolytics is working to develop next generation oncolytic viral therapies, pioneering a new approach to develop efficacious, targeted candidates suitable for systemic intravenous delivery. The company is focused on the clinical development of its lead program, with the ambition of providing better outcomes for patients with ovarian cancer. Theolytics is backed by international life sciences investors M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures and The University of Oxford.